UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.339

Sortiert nach

Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease

Frontiers in aging neuroscience, 2020-09, Vol.12, p.242-242

2020

Link zum Volltext

Verfügbarkeit prüfen

A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease

Experimental gerontology, 2017-08, Vol.94, p.103-107

2017

Link zum Volltext

Verfügbarkeit prüfen

Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation

Frontiers in immunology, 2020-03, Vol.11, p.293

2020

Link zum Volltext

Verfügbarkeit prüfen

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466

Neuropsychopharmacology (New York, N.Y.), 2008-05, Vol.33 (6), p.1323-1335

2008

Link zum Volltext

Verfügbarkeit prüfen

Differential contribution of THIK-1 K + channels and P2X7 receptors to ATP-mediated neuroinflammation by human microglia

Journal of neuroinflammation, 2024-02, Vol.21 (1), p.58-58

2024

Link zum Volltext

Verfügbarkeit prüfen

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

The Journal of pharmacology and experimental therapeutics, 2007-06, Vol.321 (3), p.1032

2007

Link zum Volltext

Verfügbarkeit prüfen

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity

The Journal of pharmacology and experimental therapeutics, 2007-01, Vol.320 (1), p.486

2007

Link zum Volltext

Verfügbarkeit prüfen

Activation of 5-HT6 receptors facilitates attentional set shifting

Psychopharmacologia, 2010-01, Vol.208 (1), p.13-21

2010

Link zum Volltext

Verfügbarkeit prüfen

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice

European journal of pharmacology, 2009-01, Vol.603 (1-3), p.147-149

2009

Link zum Volltext

Verfügbarkeit prüfen

Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR

Neuropharmacology, 2009-05, Vol.56 (6), p.1060-1067

2009

Link zum Volltext

Verfügbarkeit prüfen

The two pore potassium channel THIK‐1 regulates NLRP3 inflammasome activation

Glia, 2022-07, Vol.70 (7), p.1301-1316

2022

Link zum Volltext

Verfügbarkeit prüfen

Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania

The international journal of neuropsychopharmacology, 2011-09, Vol.14 (8), p.1051-1067

2011

Link zum Volltext

Verfügbarkeit prüfen

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes

Molecular and cellular neuroscience, 2003-11, Vol.24 (3), p.646-655

2003

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study

Journal of psychopharmacology (Oxford), 2002-12, Vol.16 (4), p.297-304

2002

Link zum Volltext

Verfügbarkeit prüfen

SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test

Neuropsychopharmacology (New York, N.Y.), 2007-10, Vol.32 (10), p.2163-2172

2007

Link zum Volltext

Verfügbarkeit prüfen

Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist

Bioorganic & medicinal chemistry letters, 2024-03, Vol.100, p.129629-129629, Article 129629

2024

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2008-06, Vol.33 (7), p.1642-1652

2008

Link zum Volltext

Verfügbarkeit prüfen

Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats

European neuropsychopharmacology, 2009-11, Vol.19 (11), p.778-790

2009

Link zum Volltext

Verfügbarkeit prüfen

Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction

Journal of medicinal chemistry, 2023-09, Vol.66 (17), p.11718-11731

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists

Journal of medicinal chemistry, 2023-09, Vol.66 (18), p.12858-12876

2023

Link zum Volltext

Verfügbarkeit prüfen

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)

The Journal of pharmacology and experimental therapeutics, 2008-04, Vol.325 (1), p.134

2008

Link zum Volltext

Verfügbarkeit prüfen

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

The Journal of pharmacology and experimental therapeutics, 2021-06, Vol.377 (3), p.407

2021

Link zum Volltext

Verfügbarkeit prüfen

Development and application of a liquid chromatography/tandem mass spectrometric assay for measurement of N-acetylaspartate, N-acetylaspartylglutamate and glutamate in brain slice superfusates and tissue extracts

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008-12, Vol.876 (2), p.153-158

2008

Link zum Volltext

Verfügbarkeit prüfen

The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?

Expert opinion on drug discovery, 2013-12, Vol.8 (12), p.1529-1539

Dawson, Lee A

2013

Link zum Volltext

Verfügbarkeit prüfen

Vilazodone: A 5‐HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders

CNS neuroscience & therapeutics, 2009-06, Vol.15 (2), p.107-117

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.339

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.173)
Mit Volltextzugriff
(1.163)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(791)
Life Sciences & Biomedicine
(593)
Humans
(434)
Male
(243)
Female
(212)
Animals
(207)
Biological And Medical Sciences
(136)
Adult
(123)
Middle Aged
(120)
Physical Sciences
(114)
Aged
(110)
Mice
(107)
Medical Sciences
(104)
Technology
(95)
Neurosciences & Neurology
(76)
Biochemistry & Molecular Biology
(74)
Physics
(74)
Neurosciences
(73)
Science & Technology - Other Topics
(61)
Child
(59)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Strabismus
(25)
Plos One
(23)
Journal Of Aapos
(20)
Proceedings Of The National Academy Of Sciences - Pnas
(19)
Alzheimer's & Dementia
(17)
Human Molecular Genetics
(15)
Journal Of Bone And Mineral Research
(13)
Neuropharmacology
(13)
Blood
(12)
Nature Communications
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease

A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease

Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466

Differential contribution of THIK-1 K + channels and P2X7 receptors to ATP-mediated neuroinflammation by human microglia

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity

Activation of 5-HT6 receptors facilitates attentional set shifting

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice

Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR

The two pore potassium channel THIK‐1 regulates NLRP3 inflammasome activation

Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes

Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study

SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test

Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist

In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia

Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats

Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

Development and application of a liquid chromatography/tandem mass spectrometric assay for measurement of N-acetylaspartate, N-acetylaspartylglutamate and glutamate in brain slice superfusates and tissue extracts

The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?

Vilazodone: A 5‐HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders

Suchergebnisse filtern